RESUMEN
BACKGROUND: While studies from large cities affected by coronavirus disease 2019 (COVID-19) have reported on the prevalence of SARS-CoV-2 in the context of universal testing during admission for delivery, the patient demographic, social and clinical factors associated with SARS-CoV-2 infection in pregnant women are not fully understood. OBJECTIVE: To evaluate the epidemiological factors associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in women admitted for labour and delivery, in the context of universal screening at four Boston-area hospitals. METHODS: In this prospective cohort study, we reviewed the health records of all women admitted for labour and delivery at four hospitals from the largest health system in Massachusetts between 19 April 2020 and 27 June 2020. We calculated the risk of SARS-CoV-2 infection, including asymptomatic infection. We calculated associations between SARS-CoV-2 infection and demographic and clinical characteristics. RESULTS: A total of 93 patients (3.2%, 95% confidence interval 2.5, 3.8) tested positive for SARS-CoV-2 infection on admission for labour and delivery out of 2945 patients included in the analysis; 80 (86.0%) of the patients who tested positive were asymptomatic at the time of testing. Factors associated with SARS-CoV-2 infection included the following: younger age, obesity, African American or Hispanic race/ethnicity, residence in heavily affected communities (as measured in cases reported per capita), presence of a household member with known SARS-CoV-2 infection, non-health care essential worker occupation and MassHealth or Medicaid insurance compared to commercial insurance. 93.8% of patients testing positive for SARS-CoV-2 on admission had one or more identifiable factors associated with disease acquisition. CONCLUSIONS: In this large sample of deliveries during the height of the surge in infections during the spring of 2020, SARS-CoV-2 infection was largely concentrated in patients with distinct demographic characteristics, those largely from disadvantaged communities. Racial disparities seen in pregnancy persist with respect to SARS-CoV-2 infection.
Asunto(s)
COVID-19/epidemiología , Complicaciones Infecciosas del Embarazo/epidemiología , Complicaciones Infecciosas del Embarazo/virología , Adulto , COVID-19/complicaciones , COVID-19/diagnóstico , Femenino , Hospitalización , Humanos , Massachusetts , Embarazo , Complicaciones Infecciosas del Embarazo/diagnóstico , Prevalencia , Estudios Prospectivos , Factores Socioeconómicos , Adulto JovenAsunto(s)
Anestesia Obstétrica , Femenino , Humanos , Sistemas de Atención de Punto , Embarazo , UltrasonografíaAsunto(s)
Infecciones por Coronavirus/epidemiología , Visita a Consultorio Médico/estadística & datos numéricos , Neumonía Viral/epidemiología , Atención Prenatal/estadística & datos numéricos , Betacoronavirus , Boston , COVID-19 , Estudios de Casos y Controles , Femenino , Humanos , Obstetricia , Pandemias , Aceptación de la Atención de Salud/estadística & datos numéricos , Embarazo , Factores de Riesgo , SARS-CoV-2RESUMEN
Therapeutic duration of traditional local anesthetics when used in peripheral nerve blocks is normally limited. This article describes novel approaches to extend the duration of peripheral nerve blocks currently available or in development. Three newer approaches on extending the duration of peripheral nerve blocks include site-1 sodium channel blockers, novel local anesthetics delivery systems, and novel adjuvants of local anesthetics. Compared with plain amide-based and ester-based local anesthetics, alternative approaches show significant promise in decreasing postoperative pain, rescue opioid requirement, hospital length-of-stay, and overall health care cost, without compromising the established safety profile of traditional local anesthetics.
Asunto(s)
Anestesia , Anestésicos Locales/farmacología , Bloqueo Nervioso/métodos , Anestesia Local , Dexmedetomidina/farmacología , Humanos , Magnesio/farmacología , Dolor Postoperatorio/prevención & control , Bloqueadores de los Canales de Sodio/farmacología , Factores de TiempoRESUMEN
Although some studies have examined the efficacy and safety of remifentanil in patients undergoing neurosurgical procedures, none has examined its safety in transsphenoidal operations specifically. In this study, all transsphenoidal operations performed by a single author from 2008 to 2015 were retrospectively reviewed to evaluate the safety of remifentanil in a consecutive series of patients. During the study period, 540 transsphenoidal operations were identified. Of these, 443 (82.0%) patients received remifentanil intra-operatively; 97 (18.0%) did not. The two groups were well-matched with regard to demographic categories, comorbidities, and pre-operative medications (p>0.05), except pre-operative tobacco use (p=0.021). Patients were also well-matched with regard to radiographic features and surgical techniques. Patients who received remifentanil were more likely to harbor a macroadenoma (78.1% vs. 67.0%, p=0.025), and had slightly longer anesthesia time on average (269.2minvs. 239.4min, p=0.024). All pathologic diagnoses were well-matched between the two groups, except that patients receiving remifentanil were more likely to harbor a non-functioning adenoma (46.5% vs. 26.8%, p<0.001). Analysis of post-operative complications showed no significant difference between patients who received remifentanil and those who did not, and length of stay and prevalence of ICU stay did not differ between the two groups. In a well-matched series of 540 patients undergoing transsphenoidal surgery, remifentanil was found to be a safe anesthetic adjunct. There were no significant differences in post-operative hospital course or complications in patients who did and did not receive intra-operative remifentanil.
Asunto(s)
Anestésicos Intravenosos/administración & dosificación , Procedimientos Neuroquirúrgicos , Piperidinas/administración & dosificación , Complicaciones Posoperatorias/diagnóstico , Seno Esfenoidal/cirugía , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anestésicos Intravenosos/efectos adversos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Procedimientos Neuroquirúrgicos/efectos adversos , Piperidinas/efectos adversos , Complicaciones Posoperatorias/inducido químicamente , Remifentanilo , Estudios Retrospectivos , Adulto JovenRESUMEN
The Kv7 (KCNQ) family of voltage-gated K(+) channels regulates cellular excitability. The functional role of Kv7.2 has been hampered by the lack of a viable Kcnq2-null animal model. In this study, we generated homozygous Kcnq2-null sensory neurons using the Cre-Lox system; in these mice, Kv7.2 expression is absent in the peripheral sensory neurons, whereas the expression of other molecular components of nodes (including Kv7.3), paranodes, and juxtaparanodes is not altered. The conditional Kcnq2-null animals exhibit normal motor performance but have increased thermal hyperalgesia and mechanical allodynia. Whole-cell patch recording technique demonstrates that Kcnq2-null sensory neurons have increased excitability and reduced spike frequency adaptation. Taken together, our results suggest that the loss of Kv7.2 activity increases the excitability of primary sensory neurons.
Asunto(s)
Ganglios Espinales/citología , Regulación de la Expresión Génica/genética , Canal de Potasio KCNQ2/metabolismo , Potenciales de la Membrana/genética , Proteínas del Tejido Nervioso/metabolismo , Células Receptoras Sensoriales/fisiología , Animales , Moléculas de Adhesión Celular Neuronal/metabolismo , Femenino , Hiperalgesia/genética , Canal de Potasio KCNQ2/genética , Canal de Potasio KCNQ3/metabolismo , Masculino , Potenciales de la Membrana/efectos de los fármacos , Ratones , Ratones Noqueados , Actividad Motora/genética , Mutación/genética , Proteínas del Tejido Nervioso/genética , Factor de Transcripción PAX3 , Umbral del Dolor/fisiología , Factores de Transcripción Paired Box/genética , Factores de Transcripción Paired Box/metabolismo , Bloqueadores de los Canales de Potasio/farmacología , Células Receptoras Sensoriales/efectos de los fármacos , Tetraetilamonio/farmacología , Canales de Sodio Activados por Voltaje/metabolismoRESUMEN
Kv7 (KCNQ) potassium channel openers (enhancers) decrease neuropathic pain in experimental models. Here we show that C-fibers, and their associated small-diameter neurons in the dorsal root ganglia (both IB4- and TrkA-positive), expressed Kv7.5. In contrast, C-fibers did not express detectable levels of Kv7.2 or Kv7.3, which are instead localized to nodes of Ranvier and the cell bodies of large sensory neurons. These data suggest that Kv7.5 provides the primary M current in nociceptive neurons.